Study wrapper · #777
Comparative Effectiveness and Safety of Once-Weekly Injectable Semaglutide Versus Dulaglutide in Individuals with Type 2 Diabetes Managed in UK Primary Care: A Population-Based Cohort Study.
Editor's note
This UK primary-care cohort (IMRD/THIN, 6,616 new users) compared once-weekly semaglutide against dulaglutide in type 2 diabetes using a new-user, active-comparator design with marginal structural models. Researchers reported semaglutide achieved greater one-year reductions in HbA1c (-0.22 percentage points) and bodyweight (-1.92 kg) than dulaglutide, with benefits preserved among the roughly 88% who would not have qualified for the SUSTAIN-7 trial. Early discontinuers had attenuated effects and higher gastrointestinal event rates. As an observational study it cannot fully exclude confounding, but its direction and magnitude echo the SUSTAIN-7 randomised trial, which strengthens confidence. For readers, it is a useful real-world confirmation that semaglutide's edge over dulaglutide extends to routine patients outside strict trial criteria, while the absolute differences are modest.
Plain-language abstract
Using UK family-practice records, researchers compared adults with type 2 diabetes who started weekly semaglutide with those who started dulaglutide, another once-weekly injection. After one year, people on semaglutide had slightly larger drops in long-term blood sugar (HbA1c) and in body weight than those on dulaglutide. Importantly, this advantage held even for the large majority of patients who would not have met the strict entry rules of the earlier SUSTAIN-7 trial, suggesting the findings apply to everyday patients. People who stopped their drug early saw smaller benefits and reported more stomach and gut side effects. Because this used real-world records rather than random assignment, it cannot completely rule out other explanations, but the results line up with the earlier randomised trial, which makes them more convincing. The differences, while real, were modest.